After 2 randomized clinical trials found it as safe and effective as the standard 3-drug regimen, the FDA approved the first 2-drug regimen for adults with HIV-1 who have never been treated with ART.
Guidelines from the American Academy of Neurology recommend stopping disease modifying therapy in those without relapsing MS and who are nonambulatory. Researchers of a study presented at ACTRIMS Forum 2019...
Researchers compared IFN production of patients with systemic lupus erythematosus who received a monoclonal antibody with those who received placebo to determine any improvement in disease activity.
The American College of Rheumatology and National Psoriasis Foundation released a guideline of recommendations for active PsA among treatment‐naïve individuals.
Hepatitis C viremia and HIV viremia were the greatest predictors of acute kidney injury (AKI) during treatment with tenofovir disoproxil fumarate (TDF), according to the r
What challenges do you see with your asthma patients? This was the subject of Dr Lily Higgins’ session at the American Lung Association’s LUNGFORCE Expo 2019. See what challenges were discussed here.
After a clinical trial demonstrated its efficacy, the FDA approved a new treatment option for adult and pediatric patients with a rare, inherited metabolic disorder.
